V. Mehraj, R. Ponte, and J. P. Routy, The dynamic role of the IL-33/ST2 axis in chronic viral-infections: alarming and adjuvanting the immune response, EBioMedicine, vol.9, pp.37-44, 2016.

V. Mehraj, M. A. Jenabian, and R. Ponte, The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection, AIDS, vol.30, issue.10, pp.1617-1644, 2016.

C. Psomas, M. Younas, and C. Reynes, One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study, EBioMedicine, vol.8, pp.265-76, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01351341

E. A. Secemsky, R. Scherzer, and E. Nitta, Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals, JACC Heart Fail, vol.3, pp.591-600, 2015.

P. Corbeau and J. Reynes, Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection, Blood, vol.117, issue.21, pp.5582-90, 2011.

L. Q. Chen, J. A. De-lemos, S. R. Das, C. R. Ayers, and A. Rohatgi, Soluble ST2 is associated with all-cause and cardiovascular mortality in a populationbased cohort: the Dallas Heart Study, Clin Chem, vol.59, issue.3, pp.536-582, 2013.

P. W. Hunt, E. Sinclair, and B. Rodriguez, Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection, J Infect Dis, vol.210, issue.8, pp.1228-1266, 2014.

A. M. Miller, D. Xu, and D. L. Asquith, IL-33 reduces the development of atherosclerosis, J Exp Med, vol.205, issue.2, pp.339-385, 2008.